BridgeBio Pharma (BBIO) Operating Margin (2019 - 2026)

BridgeBio Pharma has disclosed Operating Margin across 8 years of filings, most recently posting 54.47% for Q1 2026.

• Operating Margin for Q1 2026 came in at 54.47%, up 3502.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 90.52% (up 45705.0% YoY), and the FY2025 annual result was 104.25%, up 16297.0% from the prior year.
• Operating Margin came in at 54.47% for Q1 2026 at BridgeBio Pharma, up from 90.52% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 0.16% in Q1 2024 to a low of 38200.0% in Q3 2022.
• The 5-year median for Operating Margin is 3854.61% (2023), against an average of 6161.19%.
• Across the five-year window, Operating Margin slumped 3182206 bps in 2022 and jumped 3434539 bps in 2023, its largest moves.
• BridgeBio Pharma's Operating Margin stood at 6910.8% in 2022, then slumped by 47 bps to 10167.11% in 2023, then surged by 62 bps to 3842.69% in 2024, then soared by 98 bps to 90.52% in 2025, then soared by 40 bps to 54.47% in 2026.
• The last three Operating Margin figures came in at 54.47% (Q1 2026), 90.52% (Q4 2025), and 120.3% (Q3 2025), per Business Quant data.